Nelumal A, the active principle of Ligularia nelumbifolia was preliminarily tested as an aromatase inhibitors in HEK293 cells transfected with aromatase cDNA and using anastrazole as the reference drug. This screening revealed that it showed an appreciable level of inhibition. Subsequent experiments aimed to evaluate the aromatase activity and expression in KGN cells confirmed that the title natural product, after an incubation of 48 h, compared favourably with anastrazole (1 M) in the concentration range 10 -30 M. Moreover, nelumal A (30 M) abolished the aromatase mRNA expression in the same cell line.
Aromatase is a member of the cytochrome P450 family (EC 1.14.14.1) and is the enzyme that catalyzes the main step along the biosynthetic pathway of estrogen hormones. In particular aromatase promotes the aromatization of ring A of the steroidal nucleus thus transforming androstenedione to estrone and testosterone to estradiol. The involvement of aromatase in the pathogenesis of genetic disorders like aromatase excess [1] and deficiency [2] associated syndromes and several other diseases like breast cancer [3] , endometriosis [4] , and infertility [5] is well documented. Therapeutic means, for example, aromatase inhibitors, are now available for the management of the above listed disorders. In this context several natural products like resveratrol, myosmine, green tea catechins, apigenin, eryodictiol, isoliquiritigenin, and mangostine have been recently shown to exert promising effects as aromatase inhibitors [6] .
Our ongoing studies are aimed at the better characterization of the phytochemical and pharmacological properties of natural and semisynthetic oxyprenylated and azoprenylated secondary metabolites, and in this work we investigated the effect of nelumal A [(2E)-3-(4-((E)3,7-dimethylocta-2,6-dienyloxy)-3,5-dimethoxyphenyl)acrylaldehyde] (1), the active principle of the Chinese medicinal plant Ligularia nelumbifolia Hand. Mazz. on aromatase, using HEK and KGN cells. The first screening of the inhibitory capacity of compound 1 was accomplished using HEK (human embryonic kidney) 293 cells transfected with aromatase cDNA. The results for the enzyme inhibitory activity of nelumal A, assayed in the dose range 0.1 -10 M, are reported in Figure 1 , in comparison with that of the therapeutically used aromatase inhibitor anastrazole, used as the reference drug at a concentration of 1 M. Compound 1 was then assayed in the KGN (human ovary granulosa-like carcinoma) cell line, well known to constitutively present aromatase activity. Nevertheless, we used FSK/PMA to stimulate the cAMP/PKA-and PKC-dependent signaling in order to increase robustly aromatase expression. KGN cells were incubated for up to 48 h with nelumal A assayed in the concentration range 1.0 -30 M. Values were recorded after 3 h and at the end of the experiment. Results are reported in Figure 2 . After 48 h of pretreatment, compound 1 significantly inhibited aromatase activity. This effect was even higher than that of anastrozole (1 M) at concentrations of 10 and 30 M. We then asked whether this inhibitory effect is due to a competitive mechanism by incubating this phytochemical simultaneously with the substrate for only 3 h. Surprisingly, nelumal A did not decrease the activity of aromatase in this condition, suggesting that its inhibitory effect is not due to the competitive inhibition of aromatase and may be acting through other mechanisms which are still to be elucidated. Anastrozole, which is known as a competitive inhibitor, on the other hand showed a significant inhibition after 3 and 48 h. In order to understand further the mechanism that underpins the inhibitory effect of compound 1, we quantified the aromatase mRNA level by real time PCR. Results are reported in Figure 3 .
As expected, anastrozole did not decrease the expression of aromatase transcript. Interestingly, nelumal A followed the same pattern implying that they could be allosteric inhibitors with a capacity to bind to an allosteric site other than or in addition to the active site on the target. Further studies are needed in order to unfold the mechanism of action of 1. In conclusion, the findings described herein indicate that nelumal A could be regarded as a potential novel and effective aromatase inhibitory agent in two human cell lines, with potency comparable with that of the nonsteroidal drug anastrazole. The title natural compound has been recently reported to act as an agonist of the farnesoid X receptor [7] .
Experimental

Compound 1:
The synthesis of compound 1 was accomplished according to the procedures described previously [7] .
Cell cultures: Human embryonic kidney 293T cell line (HEK293T)
that contains the SV40 Large T-antigen and human granulosa-like tumor cell line (KGN) were grown in Dulbecco's modified Eagle medium/Ham's F-12 nutrient mix (DMEM/F-12) medium (Invitrogen, Australia) supplemented with 5%, v/v, fetal bovine serum (FBS), 50 U/mL penicillin, and 50 μg/mL streptomycin in 175-cm 2 cell culture flasks at 37°C in a humidified atmosphere containing 5% CO 2 . Cells were passaged every 2 to 3 days when they reached confluence by treating them for 5 min with 0.05% trypsin and then replating them.
Aromatase activity:
In the first set of experiments we tested the ability of nelumal A to activate aromatase in cell-based assays. HEK293T cells were transiently transfected with the aromatase cDNA (250 ng) or vector plasmid (250 ng) using Lipofectamine Reagent (Invitrogen, Australia). They were then treated with a concentration range from 0.1 to 10 µM of the title compound. Cells treated with anastrozole and DMSO served as positive and negative controls, respectively. In the second set of experiments, aromatase expression was induced by Forskolin (FSK; 25 μM) and phorbol 12-myristate 13-acetate (PMA; 4 nM) (Sigma-Aldrich, Sydney, Australia) in KGN cells. Cells were seeded at a density of 50000 per well in a 24 well-plate. The aromatase activity was determined by measuring the [ 3 H]H 2 O released upon the conversion of [1β-3 H]androstenedione (A) to estrone (E 1 ), as described previously [8] . Before the experiment, HEK293T and KGN cells were incubated with the compound for 24 and 48 h, respectively. KGN cells were also simultaneously exposed to nelumal A and [1β-3 H]androstenedione for 3 h. Each experiment was performed in duplicate and repeated 2 times.
RNA extraction and RT-PCR analysis:
After 48 h treatment of KGN cells with FSK/PMA and compounds, mRNA was isolated using the RNeasy Mini kit (Qiagen, Hilden, Germany) and cDNA was synthesised using AMVRT (Promega). Quantitative RT-PCR of total CYP19A1 and 18S mRNA was performed in duplicate with Roche LightCycler Systems using the primer pair termed RT-7 (Fwd) 5-TGGAAATGCTGAACCCGAT-3 and RT-8 (Rev) 5-CAGGAATCTGCCGTGGGGAT-3; and (Fwd) 5-CGGCTACCACATCCAAGGA-3 and (Rev) 5-GCTGGAATTACCGCGGCT-3, respectively.
Statistical analysis was performed using Prism 6.0 software (GraphPad software Inc.). Newman-Keuls Multiple Comparisons Test was also used, and a p value <0.05 was considered significant. 
